Conhecido como “Vovô do Rock” e também chamado de “dinossauro do rock”, Humberto Lane quer uma oportunidade para mostrar seu trabalho na televisão. Depois de voltar aos lançamentos autorais após cerca ...
Ginkgo Bioworks has sold an autonomous laboratory system to Novo Nordisk, marking a shift from selling fermentation services to selling the robotic infrastructure itself. The system is built around ...
The delay comes down to issues the FDA uncovered during a pre-license inspection of Novo’s Frehemgo manufacturing site after its review submission last fall. (iStock/Getty Images Plus) Already ...
Oct 2 (Reuters) - The US FDA has extended its review of Novo Nordisk's (NOVOb.CO), opens new tab experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish ...
On Sept. 24, Novo announced an agreement with Nanexa, a drug delivery company based in Sweden. As part of the deal, Nanexa will license its proprietary PharmaShell long-acting drug-delivery technology ...
Danish pharmaceutical company Novo Nordisk announced a new brand identity on September 14, 2026. The everyday brand name was shortened to 'Novo,' and the logo, colors, and typeface were changed. The ...
We have already seen results from some of ribupatide's studies, including those conducted in China. And so far, it looks promising. Kailera's pipeline also includes KAI-7535, an investigational oral ...
Novo Nordisk trades at a discount to sector earnings multiples but appears expensive on free cash flow due to elevated capex. Management's guidance to normalize capex by 2030 is pivotal; free cash ...
“Like any business, Novo regularly evaluates its organization to ensure we are positioned to meet evolving market dynamics and patient needs,” a company spokesperson said in a statement confirming the ...
Novo Nordisk has more than 1.5 million people on the Wegovy pill globally as its popularity remains strong. Globally, more than 46 million people are on obesity and diabetes treatments, showing the ...
Novo Nordisk NOVO.B1.83%increase; up pointing triangle has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion. The Danish ...
Novo set to pay Hengrui up to $2.6 billion for rights to pill China develops nearly 250 experimental treatments Hengrui candidate shows potential for once-weekly dosage The deal helps Novo shore up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results